X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...
X4 Pharmaceuticals outlines expected 2026 Phase 3 trial data release for mavorixafor
X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.
CURE6h
EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS
The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...
Targeted Oncology5h
Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma
During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...
Physician's Weekly17h
Talquetamab Shows High Response Rates in Relapsed or Refractory Multiple Myeloma
The following is a summary of “Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma ...
Le Lézard4h
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...